Skip to main content
. Author manuscript; available in PMC: 2014 Nov 15.
Published in final edited form as: Clin Cancer Res. 2013 Sep 17;19(22):10.1158/1078-0432.CCR-13-0145. doi: 10.1158/1078-0432.CCR-13-0145

Figure 6.

Figure 6

Effect of OSI-906 and selumetinib alone and in combination in athymic nude mice. Mice were treated with drugs for 20 days. Tumors treated with the combination of OSI-906 and selumetinib were significantly inhibited in comparison to the control, single agent OSI-906, and single agent selumetinib groups (ANOVA p<0.05). *Indicates significant difference between combination treatment and single agent or untreated controls. (A) HCT15 (KRASMT/BRAFWT/PIK3CAMT); (B) CUCRC006 (KRASMT/BRAFWT/PIK3CAWT).